EGFR and non-small cell lung carcinoma: The ATTLAS study assessed the efficacy of ABCP, followed by maintenance atezolizumab and bevacizumab, against platinum doublet chemotherapy followed by maintenance pemetrexed in EGFR‐ or ALK‐mutated NSCLC after TKI progression.